The agency has quietly sent a CBD compliance and enforcement policy to the White House for review, a move that could bring long-overdue standards to a chaotic market while opening the door to a new layer of federal control.
The FDA has finally made a real move on CBD.
On March 13, 2026, the agency submitted a notice titled Cannabidiol (CBD) Products Compliance and Enforcement Policy to the White House Office of Information and Regulatory Affairs for review. The filing appears on Reginfo as a pending Executive Order 12866 review, and it is classified as a notice, not a proposed rule or final rule. That distinction matters, but so does the bigger point: after years of warning letters, contradictions and strategic silence, the federal government is signaling that CBD may no longer be left to drift in regulatory limbo.
That is not automatically good news.
A more coherent compliance framework could help clean up a market that has been crowded with mislabeled products and shaky claims. Consumers deserve better. Patients deserve better. So do the companies that have spent years trying to build legitimate businesses in a category where the rules were blurry, unevenly enforced and often detached from reality.
But this is also the FDA we’re talking about. In cannabis, federal oversight rarely arrives as a warm embrace. It arrives with paperwork, restrictions, gatekeeping and the kind of top-down caution that can protect the public while also making life harder for the people the plant has already been helping. Regulation can be necessary and still come with consequences. That is what makes this moment worth watching.
For years, CBD has occupied one of the strangest corners of American drug policy: legal enough to build a multibillion-dollar marketplace around, unstable enough to keep everyone guessing and politically convenient enough for Washington to …
Read More
Author: Javier Hasse / High Times
